Hims & Hers Health (NYSE:HIMS – Get Free Report) is projected to announce its earnings results after the market closes on ...

UnitedHealth Group is under investigation by the Justice Department **over its Medicare billing prac ...

Multiple scenarios could play out in 2025. These all-weather TSX stocks can mitigate risk and generate returns in every ...

I wanted to learn my grandmother’s old recipes but needed to find quality cookware to make her dishes. Here are all the ...

The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as ...

Hims & Hers Health shares swooned after the Food & Drug Administration ... were no longer on its list of drugs in short ...

Shares of Hims & Hers Health (NYSE: HIMS) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost as ...

Johnny Gaudreau's widow, Meredith Gaudreau, has shared her emotional reaction to the 'Johnny Hockey' chants that occurred ...

We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.

The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.